Medexus Signs Exclusive Canadian License and Supply Deal with ExCellThera for UM171 Cell Therapy

Medexus Pharmaceuticals has secured exclusive Canadian commercialization rights to UM171 Cell Therapy (dorocubicel), a cord blood-derived hematopoietic stem cell product conditionally authorized in Europe as Zemcelpro®, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics. For supply chain and regulatory leads building allo-HSCT infrastructure, the deal signals an early-stage positioning play ahead of a Health Canada submission timeline that could extend to 2031.

The product is a personalized cryopreserved formulation comprising UM171-expanded CD34+ cells and unexpanded CD34- cells, both derived from a single cord blood unit. The European Commission granted conditional marketing authorization for adults with hematological malignancies requiring allo-HSCT following myeloablative conditioning where no suitable alternative donor cells are available. The UM171 molecule was developed at the Université de Montréal, giving the asset a Canadian scientific provenance that Medexus cited as strategically relevant to its regulatory positioning.

Medexus does not anticipate Canadian commercialization before 2028, with a possible extension to 2031 depending on which regulatory pathway Health Canada makes available. The company intends to file for approval no later than the successful completion of a Cordex-sponsored international multi-center Phase 3 trial targeting high- and very high-risk acute leukemias and myelodysplasias, a post-authorization commitment under the European conditional approval. That trial is expected to conclude within four years of initiation.

The supply-chain read is direct: Medexus is building a cold-chain-capable allo-HSCT distribution network in Canada anchored by its existing Trecondyv® (treosulfan for injection) commercial infrastructure. With more than 843 allo-HSCT procedures recorded in Canada during calendar year 2024, the addressable patient population is defined, though the eventual product label approved by Health Canada will determine eligible patient scope. QA and logistics teams at transplant centers should note that cryopreserved personalized cell therapy products carry distinct chain-of-identity and sterility assurance requirements compared with conventional biologics, and supply agreements of this type typically require facility qualification well ahead of any regulatory submission.

Medexus has indicated it will seek Health Canada acceptance of the Zemcelpro® brand name as part of the submission process; that name has not yet been reviewed or accepted by the regulator.

The Phase 3 trial completion date will serve as the hard regulatory checkpoint against which Medexus's Canadian submission timeline, and transplant center readiness planning, should be benchmarked.

Source: Medexus Pharmaceuticals, Inc. via Newsfile Corp., June 9, 2026.